AKT1 belongs to a family of serine-threonine protein
kinases which also includes AKT2 and AKT3.
AKT1 plays a key role in multiple cell processes, including growth, proliferation, survival,
and angiogenesis. AKT1 acts as a downstream mediator of phosphatidylinositol 3-kinase (PI3K; Figure
Figure 1. Schematic of the MAPK and PI3K
pathways. Growth factor binding to receptor
tyrosine kinase results in activation of
the MAPK signaling pathway
(RAS-RAF-MEK-ERK) and the PI3K pathway (PI3K-AKT-mTOR). The letter "K" within the schema
denotes the tyrosine kinase domain.
Suggested Citation: Lovly, C., L. Horn, W. Pao. 2015. AKT1. My Cancer
(Updated December 7).
Last Updated: December 7, 2015
AKT1 in Non-Small Cell Lung Cancer (NSCLC)
Somatic mutations in AKT1 have
been found in ~ 1% of all NSCLC (Bleeker et al. 2008; Do et al. 2008;
Malanga et al. 2008),
in both adenocarcinoma and squamous cell carcinoma histology. Preclinical data have shown
that the presence of this mutation results in cellular transformation in vitro and in
vivo (Carpten et al. 2007).
Specific clinical characteristics of lung cancer patients harboring AKT1 mutations
have yet to be described.
In the vast majority of cases, AKT1 mutations
are non-overlapping with other oncogenic mutations
found in NSCLC (e.g., EGFR mutations, ALK rearrangements, etc.).
Suggested Citation: Lovly, C., L. Horn, W. Pao. 2015. AKT1 in Non-Small Cell
Lung Cancer (NSCLC). My Cancer Genome https://www.padiracinnovation.org/content/disease/lung-cancer/akt1/
(Updated June 18).
Last Updated: June 18, 2015
My Cancer Genome has released its new and improved cancer clinical trials search tool on our
beta website. Please visit beta.padiracinnovation.org
to check it out!